Good morning. Elizabeth Cooney here in Boston, filling in for Ed Silverman while he’s reporting from the J.P. Morgan Healthcare Conference in San Francisco. You can follow STAT’s team coverage of the gathering in the Readout @ JPM. Here’s what we’re watching in biopharma today:

Allergan (AGN) CEO Brent Saunders, who famously declared in 2016 that his company would keep a “social contract” by ensuring price hikes — after rebates and discounts — would remain below double digits and not exceed inflation, told STAT the company is staying true to its promise, with some hikes at 9.5 percent, some at zero, and an average of 3.5 percent across its portfolio. “I think we absolutely lived up to well beyond the spirit and heart of our social contract, because our net prices are below the cost of inflation, which means, economically, they’re in decline.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • “Well take this, Secretary Azzar, we don’t report to you anymore.” That at least is my read – “Eli Lilly (LLY) won’t put the price of its prescription drugs in television ads, as the Trump administration has called for …”
    And as of 9:27 EDT today, the link only shows the label for Trulicity, sans the Lily promised pricing data – but it is early yet at JPM so who knows?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy